Comparison of Anti-HLA Antibody Production According to Gestational Periods in Pregnant Women.
BACKGROUND
To evaluate paternal anti-HLA antibody profiles, sera samples were collected from pregnant women in different trimesters and the panel-reactive antibody (PRA) specificities were identified.


METHODS
From 2013 to 2015, serum samples were obtained from 41 pregnant women who had registered at the Izmir Tepecik Education and Research Hospital Gynecology Clinic. Anti-HLA antibodies were screened by using the panel reactive antibody screening and identification tests. Sera samples were obtained at the first, second, and third trimesters. The primary outcome was to determine the anti-HLA antibody production term during pregnancy; the secondary outcome was identification of anti-HLA antibodies.


RESULTS
None of the women had a sensitization history except during pregnancy. We observed that 54% of the women produced paternal antibodies, either class I or II. Class I PRA positivity of the women who had a first or second pregnancy was the same in all 3 trimesters, whereas class II positivity was increased in the third trimester. Class II and both class I and II positivity increased in the third trimester; class I positivity was decreased in the third trimester. PRA positivity could be affected by the history of pregnancy and could be raised, but no impact was observed from the history of abortion and miscarriage (odds ratios, 1.9, 0.4, and 0.5 [95% confidence intervals, 0.5-7.8, 0.1-2.0, and 0.3-0.7], respectively; P > .05). The most frequently detected antibodies were A2, B7, DR7, DR4, DR11, DR13, DQ2, and DQ8.


CONCLUSIONS
Anti-HLA antibodies against paternal HLA antigens were detected more in multiparous women than in primiparous women. Anti-HLA antibody detection ratios did not change until the third trimester and were followed by a specific increase in class II anti-HLA antibody production.
Izmir Katip Celebi University Faculty of Medicine, Department of Medical Biology and Genetics, Izmir, Turkey; University of Health Science Tepecik Training and Research Hospital, Tissue Typing Laboratory, Izmir, Turkey. Electronic address: burcu.cerci.gurbuz@ikc.edu.tr.
B
B
Cerci Gurbuz
Izmir Katip Celebi University Faculty of Medicine, Department of Medical Biology and Genetics, Izmir, Turkey; University of Health Science Tepecik Training and Research Hospital, Tissue Typing Laboratory, Izmir, Turkey.
M
M
Soyoz
University of Health Science Tepecik Training and Research Hospital, Clinic of Gynecology, Izmir, Turkey.
D
D
Ozkale Okyay
Izmir Katip Celebi University Faculty of Medicine, Department of Medical Biology and Genetics, Izmir, Turkey; University of Health Science Tepecik Training and Research Hospital, Tissue Typing Laboratory, Izmir, Turkey.
T
T
Kilicaslan Ayna
Izmir Katip Celebi University Faculty of Medicine, Department of Medical Biology and Genetics, Izmir, Turkey; University of Health Science Tepecik Training and Research Hospital, Tissue Typing Laboratory, Izmir, Turkey.
I
I
Pirim
D000328:Adult; D000906:Antibodies / Q000276:immunology*; D000917:Antibody Formation; D000961:Antilymphocyte Serum / Q000276:immunology; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D011247:Pregnancy / Q000276:immunology*
D000906:Antibodies; D000961:Antilymphocyte Serum; D006680:HLA Antigens